A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Drug: SHR-9539 for injection
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 138
- Registration Number
- NCT06484777
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer
Phase 2
Recruiting
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06465563
- Locations
- 🇨🇳
The First Affiliated Hospital，Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Trial of SHR-4849 in Advanced Solid Tumors
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06443489
- Locations
- 🇨🇳
Jilin Cancer Hospital, Jilin, Changchun, China
Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
Phase 1
Not yet recruiting
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- Drug: SHR-A1921；Adebrelimab；SHR-8068；carboplatin
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 124
- Registration Number
- NCT06434103
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Phase 3
Recruiting
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 440
- Registration Number
- NCT06394492
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳National Cancer Center/Tumor Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06381050
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangzhou, China
PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06380881
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer
Phase 2
Recruiting
- Conditions
- Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin InjectionDrug: Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06247956
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer
Phase 2
Not yet recruiting
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 520
- Registration Number
- NCT06211023
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
Phase 3
Recruiting
- Conditions
- Advanced Colorectal Cancer
- Interventions
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06199973
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath